Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 21, Issue 40, 2015, Pages 11273-11281

  Marín, Alicia C ^a   Gisbert, Javier P ^a   Chaparro, María ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Crohn's disease; Immunogenicity; Inflammatory bowel disease; Tumor necrosis factor; Ulcerative colitis; Vaccination; Vaccine

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; ANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; LIVE VACCINE;

ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CHICKENPOX; COMORBIDITY; CROHN DISEASE; GENETIC POLYMORPHISM; GROUPS BY AGE; HEPATITIS B; HEPATITIS B VIRUS; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INFLUENZA; INFLUENZA VACCINATION; MEASLES; MEMORY CELL; MUMPS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; RUBELLA; SEX DIFFERENCE; SMOKING HABIT; TETANUS; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; COLITIS, ULCERATIVE; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; SEROLOGY; VACCINATION;

ANTIBODIES; BIOMARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; SEROLOGIC TESTS; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84944907602     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i40.11273     Document Type: Article

References (74)

1. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558 [PMID: 18178610 DOI:10.1136/gut.2006.114660].
2. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-468 [PMID: 24613021 DOI:10.1016/j.Crohns.2013.12.013].
3. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis 2011; 17: 2536-2540 [PMID: 21538710 DOI:10.1002/ibd.21667].
4. Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2011; 11: 87 [PMID: 21798078 DOI:10.1186/1471-230X-11-87].
5. Teich N, Klugmann T, Tiedemann A, Holler B, Mössner J, Liebetrau A, SchiefkeI . Vaccinationcoveragein immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int 2011; 108: 105-111 [PMID: 21412507 DOI:10.3238/arztebl.2011.0105].
6. Altunöz ME, Senates E, Yesil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012; 57: 1039-1044 [PMID: 22147248 DOI:10.1007/s10620-011-1980-8].
7. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 851-856 [PMID: 17544875 DOI:10.1016/j.cgh.2007.02.035].
8. De Bruyn JC, Hilsden R, Fonseca K, Russell ML, Kaplan GG, Vanderkooi O, Wrobel I. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 25-33 [PMID: 21472826 DOI:10.1002/ibd.21706].
9. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 148-154 [PMID: 19755964 DOI:10.1038/ajg.2009.523].
10. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study. Inflamm Bowel Dis 2012; 18: 1042-1047 [PMID: 21674732 DOI:10.1002/ibd.21800].
11. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and Cinfection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 619-633 [PMID: 21416659 DOI:10.1111/j.1365-2036.2010.04570.x].
12. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez- Carballeira M, Fernández-Bañares F, Viver JM, Esteve M. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346 [PMID: 20577000 DOI:10.1136/gut.2010.208413].
13. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009; 15: 1410-1416 [PMID: 19462435 DOI:10.1002/ibd.20943].
14. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105: 1231-1238 [PMID: 20104218 DOI:10.1038/ajg.2009.733].
15. Coates T, Wilson R, Patrick G, André F, Watson V. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23: 392-403 [PMID: 11318074].
16. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-692 [PMID: 15472534].
17. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55: 1-33; quiz CE1-4 [PMID: 17159833].
18. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-1840 [PMID: 16817843 DOI:10.1111/j.1572-0241.2006.00646.x].
19. Vida Pérez L, Gómez Camacho F, García Sánchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, Casáis Juanena L, De Dios Vega JF. [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease]. Med Clin (Barc) 2009; 132: 331-335 [PMID: 19268981 DOI:10.1016/j.medcli.2008.07.013].
20. Gisbert JP, Villagrasa JR, Rodríguez-N ogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1460-1466 [PMID: 23034605 DOI:10.1038/ajg.2012.79].
21. Loras C, Gisbert JP, Saro MC, Piqueras M, Sánchez-Montes C, Barrio J, Ordás I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fernández-Bañares F, Esteve M. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis 2014; 8: 1529-1538 [PMID: 25052345 DOI:10.1016/j.Crohns.2014.06.009].
22. Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 1379-1385 [PMID: 22530631 DOI:10.1111/j.1365-2036.2012.05110.x].
23. Chaparro M, Gordillo J, Domenech E, Esteve M, Barreiro de- Acosta M, Villoria A, Iglesias-Flores E, Blasi M, Naves JE, Benitez O, Nieto L, Calvet X, Garcia-Sanchez V, Villagrasa JR, Marin AC, Ramas M, Moreno I, Gisbert JP. Prospective, randomized clinical trial comparing the efficacy of two vaccines against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. J Crohns Colitis 2015; 9 (Suppl.1): S299 [DOI:10.1093/ecco-jcc/jju027.557].
24. Banatvala JE, Van Damme P. Hepatitis B vaccine - do we need boosters? J Viral Hepat 2003; 10: 1-6 [PMID: 12558904].
25. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989; 87: 36S-40S [PMID: 2528297 DOI:10.1016/0002-9343(89)90530-5].
26. Jafarzadeh A, Bagheri-Jamebozorgi M, Nemati M, Golsaz-Shirazi F, Shokri F. Eukocyte Antigens Influence the Antibody Response to Hepatitis B Vaccine. Iran J Allergy Asthma Immunol 2015; In press.
27. Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA, Yunis EJ. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 1997; 58: 42-51 [PMID: 9438208].
28. Shokrgozar MA, Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 2001; 104: 75-79 [PMID: 11576223].
29. Weihrauch MR, von Bergwelt-Baildon M, Kandic M, Weskott M, Klamp W, Rosler J, Schultze JL. T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. World J Gastroenterol 2008; 14: 2529-2533 [PMID: 18442200 DOI:10.3748/wjg.14.2529].
30. Suzuki T, Yamauchi K, Kuwata T, Hayashi N. Characterization of hepatitis B virus surface antigen-specific CD4+ T cells in hepatitis B vaccine non-responders. J Gastroenterol Hepatol 2001; 16: 898-903 [PMID: 11555104].
31. Li J, Tan D, Liu H, Li K. CD4(+) CD25(+) FoxP3(+) T regulatory cells in subjects responsive or unresponsive to hepatitis B vaccination. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011; 36: 1046-1051 [PMID: 22169715 DOI:10.3969/j.issn.1672-7347.2011.11.003].
32. Albarran B, Goncalves L, Salmen S, Borges L, Fields H, Soyano A, Montes H, Berrueta L. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. APMIS 2005; 113: 526-535 [PMID: 16086823 DOI:10.1111/j.1600-0463.2005.apm-191.x].
33. Yao ZQ, Moorman JP. Immune exhaustion and immune senescence: Two distinct pathways for HBV vaccine failure during HCV and/or HIV infection. Arch Immunol Ther Exp (Warsz) 2013; 61: 193-201 [PMID: 23400275 DOI:10.1007/s00005-013-0219-0].
34. Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008; 19: 1483-1490 [PMID: 18480314 DOI:10.1681/ASN.2007090971].
35. Armstrong KE, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC. Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002-2007. J Int Assoc Physicians AIDS Care (Chic) 2010; 9: 179-186 [PMID: 20530473 DOI:10.1177/1545109710368721].
36. Sari F, Taskapan H. Good response to HBsAg vaccine in dialysis patients is associated with high CD4+/CD8+ ratio. Int Urol Nephrol 2012; 44: 1501-1506 [PMID: 21809071 DOI:10.1007/s11255-011-0043-6].
37. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-1712 [PMID: 21530736 DOI:10.1053/j.gastro.2011.02.046].
38. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak- Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genomewide meta-analysis increases to 71 the number of confirmed Crohn' s disease susceptibility loci. Nat Genet 2010; 42: 1118-1125 [PMID: 21102463 DOI:10.1038/ng.717].
39. Muñoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000; 19: 1-5 [PMID: 11091143].
40. Nowak Z, Karowicz-Bilinska A. [Human papilloma virus infection in pregnant women with normal pap-smears, HPV oncogenity and risk factors]. Ginekol Pol 2007; 78: 678-684 [PMID: 18159820].
41. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527 [PMID: 12571259 DOI:10.1056/NEJMoa021641348/6/518].
42. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255 [PMID: 16631880 DOI:10.1016/S0140-6736(06)68439-0].
43. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278 [PMID: 15863374 DOI:10.1016/S1470-2045(05)70101-7].
44. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, Renna H, Lu Y. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1441-1449 [PMID: 23567780 DOI:10.1097/MIB.0b013e318281341b].
45. Schanzer DL, Langley JM, Tam TW. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir Viruses 2008; 2: 1-8 [PMID: 19453488 DOI:10.1111/j.1750-2659.2008.00035.x].
46. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 2006; 25: 795-800 [PMID: 16940836 DOI:10.1097/01.inf.0000232632.86800.8c00006454-200609000-00008].
47. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21: 559-566 [PMID: 11983546].
48. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: The Christie hospital experience. Bone Marrow Transplant 2003; 32: 73-77 [PMID: 12815481 DOI:10.1038/sj.bmt.1704048].
49. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep 2007; 56: 1-54 [PMID: 17625497].
50. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 444-453 [PMID: 19174786 DOI:10.1038/ajg.2008.120].
51. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-716 [PMID: 17965123 DOI:10.1136/ard.2007.077552].
52. Cowan M, Chon WJ, Desai A, Andrews S, Bai Y, Veguilla V, Katz JM, Josephson MA, Wilson PC, Sciammas R, Chong AS. Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation 2014; 97: 846-853 [PMID: 24366008 DOI:10.1097/01.TP.0000438024.10375.2d].
53. Bálint A, Farkas K, Éva PK, Terhes G, Urbán E, Szucs M, Nyári T, Bata Z, Nagy F, Szepes Z, Miheller P, Lorinczy K, Lakatos PL, Lovász B, Tamás S, Kulcsár A, Berényi A, Törocsik D, Daróczi T, Saródi Z, Wittmann T, Molnár T. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. Scand J Gastroenterol 2015; 50: 174-181 [PMID: 25384624 DOI:10.3109/00365521.2014.928902].
54. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26 Suppl 4: D35-D40 [PMID: 19230157 DOI:10.1016/j.vaccine.2008.07.065].
55. Targonski PV, Poland GA. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve Clin J Med 2007; 74: 401-46, 401-46, 401-46, [PMID: 17569198].
56. Leggat DJ, Khaskhely NM, Iyer AS, Mosakowski J, Thompson RS, Weinandy JD, Westerink MA. Pneumococcal polysaccharide vaccination induces polysaccharide-specific B cells in adult peripheral blood expressing CD19+CD20+CD3-CD70-CD27+IgM+CD43+CD5+/-. Vaccine 2013; 31: 4632-4640 [PMID: 23911852 DOI:10.1016/j.vaccine.2013.07.030].
57. Leggat DJ, Thompson RS, Khaskhely NM, Iyer AS, Westerink MA. The immune response to pneumococcal polysaccharides 14 and 23F among elderly individuals consists predominantly of switched memory B cells. J Infect Dis 2013; 208: 101-108 [PMID: 23547142 DOI:10.1093/infdis/jit139].
58. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I, Carsetti R. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 939-945 [PMID: 12682112 DOI:10.1084/jem.20022020].
59. Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A, Plebani A, Aiuti F, Quinti I. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115: 412-417 [PMID: 15696104 DOI:10.1016/j.jaci.2004.10.048].
60. Di Sabatino A, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR. Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur Rev Med Pharmacol Sci 2004; 8: 199-203 [PMID: 15638230].
61. Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, Carsetti R. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 2005; 100: 1788-1795 [PMID: 16086716 DOI:10.1111/j.1572-0241.2005.41939.x].
62. Fallahi G, Aghamohammadi A, Khodadad A, Hashemi M, Mohammadinejad P, Asgarian-Omran H, Najafi M, Farhmand F, Motamed F, Soleimani K, Soheili H, Parvaneh N, Darabi B, Nasiri Kalmarzi R, Pourhamdi S, Abolhassani H, Mirminachi B, Rezaei N. Evaluation of antibody response to polysaccharide vaccine and switched memory B cells in pediatric patients with inflammatory bowel disease. Gut Liver 2014; 8: 24-28 [PMID: 24516697 DOI:10.5009/gnl.2014.8.1.24].
63. Di Sabatino A, Rosado MM, Cazzola P, Biancheri P, Tinozzi FP, Laera MR, Cantoro L, Vanoli A, Carsetti R, Corazza GR. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. Inflamm Bowel Dis 2008; 14: 591-596 [PMID: 18240280 DOI:10.1002/ibd.20374].
64. Salinas GF, De Rycke L, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, van der Burg M, Tak PP, Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037-1043 [PMID: 22968102].
65. Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol 1987; 24: 69-74 [PMID: 3437440].
66. Stevens R, Oliver M, Brogan M, Heiserodt J, Targan S. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology 1985; 88: 1860-1866 [PMID: 3873371].
67. Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyteand platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol 2001; 36: 265-269 [PMID: 11305513].
68. Bernstein CN, Rawsthorne P, Blanchard JF. Populationbased case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 759-762 [PMID: 17230540 DOI:10.1002/ibd.20089].
69. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-40 [PMID: 17585291].
70. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-2284 [PMID: 15930418 DOI:10.1056/NEJMoa051016].
71. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1-30; quiz CE2-4 [PMID: 18528318].
72. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-49 [PMID: 22760290].
73. Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis 2007; 13: 1178-1179 [PMID: 17476676 DOI:10.1002/ibd.20161].
74. Singh A, Englund K. Q: Who should receive the shingles vaccine? Cleve Clin J Med 2009; 76: 45-48 [PMID: 19122110 DOI:10.3949/ccjm.75a.08046].